AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, an American biopharmaceutical company at the clinical stage of development. CinCor Pharma is developing new treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. The deal will amount to $1.8 billion.

AstraZeneca is acquiring TeneoTwo, which is developing TNB-486 to treat relapsed and refractory B-cell non-Hodgkin's lymphoma. AstraZeneca will pay an upfront payment of $100 million and will pay up to $805 million more when certain development milestones are reached and up to $360 million when certain sales levels are reached. The deal is scheduled to close...

AstraZeneca's COVID-19 vaccine, Vaxzevria, has been approved for use in the EU as a third dose for adult revaccination. The vaccine can now be used as a booster after two doses of the company's vaccine or by those who were previously vaccinated with mRNA vaccine made by Pfizer and BioNTech or Moderna.

AstraZeneca's IFRS net income for 3 months of 2022 was $0.388 billion, down four times from $1.562 billion in the previous year. Revenue increased by 55.6% to $11.39 billion compared to $7.32 billion a year earlier.